FMP

FMP

Enter

MGTX - MeiraGTx Holdin...

photo-url-https://images.financialmodelingprep.com/symbol/MGTX.png

MeiraGTx Holdings plc

MGTX

NASDAQ

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

6.14 USD

0.12 (1.95%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. Alexandria Forbes Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomi...

CIK

0001735438

ISIN

KYG596651029

CUSIP

G59665102

Address

430 East 29th Street

Phone

646 860 7985

Country

US

Employee

387

IPO Date

Jun 8, 2018

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

MGTX Financial Summary

CIK

0001735438

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

G59665102

ISIN

KYG596651029

Country

US

Price

6.14

Beta

1.25

Volume Avg.

291.76k

Market Cap

479.86M

Shares

-

52-Week

3.85-7.6

DCF

-5.25

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.34

P/B

-

Website

https://www.meiragtx.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest MGTX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep